title: [Study on the clinical characteristics of biphenotypic acute leukemia].
abstract: OBJECTIVE
  To analyze the biological characteristics and the treatment outcome of adult biphenotypic acute leukemia.
  
  
  METHODS
  Immunophenotypes were examined using indirect immunofluorescence method. Biphenotypic acute leukemia (BAL) was diagnosed according to EGIL scoring system.
  
  
  RESULTS
  (1) The incidence of BAL in acute leukemia was 3.4%. Percentage for coexpression of B lymphoid and myeloid antigens was 68.4%, for T lymphoid and myeloid antigens 21.1%, for B, T lymphoid and myeloid antigens 10.5%. (2) CD(34) was expressed in 43.75% of the BAL cases. (3) Cytogenetic analysis revealed normal and abnormal karyotypes in 41.7% and 58.3% of the BAL cases, respectively. (4) Six of 19 patients achieved completed remission (CR), but the disease free survivals were all less than 6 months. Treatment outcomes were negatively related to the expression of CD(34) antigen and cytogenetic findings. The BAL patients were poorly responded to therapeutic regimens directed to AML.
  
  
  CONCLUSIONS
  Coexpression of B/M antigens is the commonest subtype in BAL. BAL had a poor prognosis, especially treated with induction regimen directed to AML.
authors.affiliation: Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin 300020, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Mi
authors.forename: S
authors.initials: S
authors.lastname: Bian
authors.forename: Q
authors.initials: Q
authors.lastname: Meng
authors.forename: Y
authors.initials: Y
authors.lastname: Xue
authors.forename: M
authors.initials: M
authors.lastname: Yu
authors.forename: G
authors.initials: G
authors.lastname: Chen
authors.forename: D
authors.initials: D
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: L
authors.initials: L
authors.lastname: Qian
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007621:Karyotyping; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34